Home › Metastatic Cancer › Maryland
Metastatic Cancer clinical trials in Maryland
47 studies for Metastatic Cancer are looking for participants at sites in Maryland.
Cities in Maryland
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Maryland Oncology, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07562152Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- and 1 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 5, 2026 · NCT05564377The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 98 · All sexes · Updated Oct 5, 2026 · NCT04927416Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Greater Baltimore Medical Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07222800A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- JHU Oncology Central Kit Services, Baltimore
- Johns Hopkins Hospital, Baltimore
- Oncology Investigational Drug Service (IDS), Baltimore
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06989437Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Maryland Oncology Hematology, P.A., Annapolis
- Maryland Oncology Hematology, P.A., Bethesda
- Maryland Oncology Hematology, P.A., Brandywine
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- John Hopkins University, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06915753A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital Of Baltimore, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Johns Hopkins Hospital, Baltimore
- James M Stockman Cancer Institute, Frederick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- American Oncology Partners, PA, Bethesda
- James M Stockman Cancer Institute, Frederick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174336Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06606990The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 90 · All sexes · Updated Sep 9, 2026 · NCT03841617Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT03907475A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Johns Hopkins Bayview Medical Center, Baltimore
- USO - Maryland Oncology Hematology, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
- Johns Hopkins, Baltimore
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 8, 2026 · NCT07563829Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Aug 31, 2026 · NCT02133196Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT05687136FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Johns Hopkins Kimmel Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
- Research Site, Baltimore
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Aug 18, 2026 · NCT06792695FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT05691517Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05687110Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT05691491A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Silver Spring
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336REMASTer: REcurrent Brain Metastases After SRS Trial
- University of Maryland, Baltimore
Recruiting
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT05124912E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT05686226Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Advanced Molecular Imaging and Therapy, Glen Burnie
- United Theranostics - Chesapeake, Glen Burnie
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05283330Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Johns Hopkins University, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT06040541Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- University of Maryland, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 2, 2026 · NCT04617522A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- John Hopkins University, Baltimore
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT05384626Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- American Oncology Partners, P.A., Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 18, 2026 · NCT06757634Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Johns Hopkins University, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985Studying TAK-243 in Patients With Advanced Cancer
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT06223542Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- The Center for Cancer and Blood Disorders, Bethesda
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT06697301A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Johns Hopkins University, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT07020221A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Maryland, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06064877Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
RecruitingPhase 2/3
Ages 18 and older · Men · Updated Apr 8, 2026 · NCT04787744From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.